First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM

Open source

DOI: 10.1093/oncolo/oyad338
Published: 2024 Apr 4
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyad338,
  title = {First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.},
  author = {Piha-Paul SA and Xu B and Dumbrava EE and Fu S and Karp DD and Meric-Bernstam F and Hong DS and Rodon JA and Tsimberidou AM and Raghav K and Ajani JA and Conley AP and Mott F and Fan Y and Fan J and Peng P and Wang H and Ni S and Sun C and Qiang X and Levin WJ and Ngo B and Ru QC and Wu F and Javle MM},
  year = {2024},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyad338},
  url = {https://doi.org/10.1093/oncolo/oyad338}
}

RIS

TY  - JOUR
TI  - First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
AU  - Piha-Paul SA
AU  - Xu B
AU  - Dumbrava EE
AU  - Fu S
AU  - Karp DD
AU  - Meric-Bernstam F
AU  - Hong DS
AU  - Rodon JA
AU  - Tsimberidou AM
AU  - Raghav K
AU  - Ajani JA
AU  - Conley AP
AU  - Mott F
AU  - Fan Y
AU  - Fan J
AU  - Peng P
AU  - Wang H
AU  - Ni S
AU  - Sun C
AU  - Qiang X
AU  - Levin WJ
AU  - Ngo B
AU  - Ru QC
AU  - Wu F
AU  - Javle MM
PY  - 2024
JO  - The oncologist
DO  - 10.1093/oncolo/oyad338
UR  - https://doi.org/10.1093/oncolo/oyad338
ER  -

APA

SA, P., B, X., EE, D., S, F., DD, K., F, M., DS, H., JA, R., AM, T., K, R., JA, A., AP, C., F, M., Y, F., J, F., P, P., H, W., S, N., C, S., X, Q., WJ, L., B, N., QC, R., F, W., & MM, J. (2024). First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.. The oncologist. https://doi.org/10.1093/oncolo/oyad338

Source records

pubmed · retrieved 2026-09-27T09:33:21.269Z